carvedilol has been researched along with Bradycardia in 11 studies
Bradycardia: Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Large randomized trials have reported mixed results regarding the risk of bradycardia between metoprolol and carvedilol." | 7.79 | Risk of emergent bradycardia associated with the use of carvedilol and metoprolol in routine clinical practice. ( Pletcher, MJ; Shin, J, 2013) |
| "beta-blockers (BB) in the treatment of heart failure (HF) are frequently underprescribed and underdosed, perhaps because of recommendations for office visits at each dose change." | 5.32 | Remote titration of carvedilol for heart failure patients by advanced practice nurses. ( Mischke, L; Moyer-Knox, D; Mueller, TM; Vuckovic, K; Williams, RE, 2004) |
| "Large randomized trials have reported mixed results regarding the risk of bradycardia between metoprolol and carvedilol." | 3.79 | Risk of emergent bradycardia associated with the use of carvedilol and metoprolol in routine clinical practice. ( Pletcher, MJ; Shin, J, 2013) |
| " Two strategies were evaluated: (1) conventional therapy (conventional)-the risks for death and hospitalization were derived from the angiotensin-converting enzyme inhibitor arm of the SOLVD treatment trial; and (2) pacemaker insertion with atrial pacing and carvedilol therapy (pacemaker-carvedilol)-risk reductions for death and CHF-related hospitalizations for carvedilol compared with conventional therapy were derived from the US Carvedilol Heart Failure Study." | 3.73 | Prophylactic pacemaker use to allow beta-blocker therapy in patients with chronic heart failure with bradycardia. ( Aaronson, KD; Fendrick, AM; Knight, BP; Stecker, EC, 2006) |
| "Beta-blockers substantially improve survival in patients with chronic heart failure (HF) with left ventricular systolic dysfunction, but concerns about cardiovascular adverse effects may deter physicians from prescribing this therapy." | 2.71 | Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. ( Coffey, CS; Curtis, JP; Foody, JM; Hebert, PR; Ko, DT; Krumholz, HM; Sedrakyan, A, 2004) |
| "Flushing and erythema are frequent skin symptoms in rosacea." | 2.66 | Use of beta-blockers for rosacea-associated facial erythema and flushing: A systematic review and update on proposed mode of action. ( Driessen, RJB; Logger, JGM; Olydam, JI, 2020) |
| "Carvedilol treatment resulted in less left ventricular hypertrophy and dilatation." | 1.37 | Usefulness of carvedilol in the treatment of chronic aortic valve regurgitation. ( Arsenault, M; Couet, J; Lachance, D; Roussel, E; Zendaoui, A, 2011) |
| "beta-blockers (BB) in the treatment of heart failure (HF) are frequently underprescribed and underdosed, perhaps because of recommendations for office visits at each dose change." | 1.32 | Remote titration of carvedilol for heart failure patients by advanced practice nurses. ( Mischke, L; Moyer-Knox, D; Mueller, TM; Vuckovic, K; Williams, RE, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Stone, KH | 1 |
| Reynolds, K | 1 |
| Davis, S | 1 |
| Van Tassell, BW | 1 |
| Gibson, CM | 1 |
| Srivastava, S | 1 |
| Kemnic, T | 1 |
| Hildebrandt, KR | 1 |
| Logger, JGM | 1 |
| Olydam, JI | 1 |
| Driessen, RJB | 1 |
| Shin, J | 1 |
| Pletcher, MJ | 1 |
| Nabeta, T | 1 |
| Inomata, T | 1 |
| Iida, Y | 1 |
| Ikeda, Y | 1 |
| Iwamoto-Ishida, M | 1 |
| Ishii, S | 1 |
| Naruke, T | 1 |
| Mizutani, T | 1 |
| Shinagawa, H | 1 |
| Koitabashi, T | 1 |
| Takeuchi, I | 1 |
| Ako, J | 1 |
| Zendaoui, A | 1 |
| Lachance, D | 1 |
| Roussel, E | 1 |
| Couet, J | 1 |
| Arsenault, M | 1 |
| Cohen-Solal, A | 1 |
| Logeart, D | 1 |
| Guiti, C | 1 |
| Bourgoin, P | 1 |
| Moyer-Knox, D | 1 |
| Mueller, TM | 1 |
| Vuckovic, K | 1 |
| Mischke, L | 1 |
| Williams, RE | 1 |
| Ko, DT | 1 |
| Hebert, PR | 1 |
| Coffey, CS | 1 |
| Curtis, JP | 1 |
| Foody, JM | 1 |
| Sedrakyan, A | 1 |
| Krumholz, HM | 1 |
| Stecker, EC | 1 |
| Fendrick, AM | 1 |
| Knight, BP | 1 |
| Aaronson, KD | 1 |
1 review available for carvedilol and Bradycardia
| Article | Year |
|---|---|
Use of beta-blockers for rosacea-associated facial erythema and flushing: A systematic review and update on proposed mode of action.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Bradycardia; Carvedilol; Dermatologic Agents; Dru | 2020 |
1 trial available for carvedilol and Bradycardia
| Article | Year |
|---|---|
Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Bradycardia; Carbazoles; Carvedilol; Dizziness; Fatig | 2004 |
9 other studies available for carvedilol and Bradycardia
| Article | Year |
|---|---|
Comparison of new-onset post-operative atrial fibrillation between patients receiving carvedilol and metoprolol after off-pump coronary artery bypass graft surgery.
Topics: Adrenergic beta-Antagonists; Adult; Atrial Fibrillation; Bradycardia; Carvedilol; Coronary Artery By | 2023 |
BRASH syndrome.
Topics: Antihypertensive Agents; Atrioventricular Block; Bradycardia; Bumetanide; Carvedilol; Female; Humans | 2020 |
Risk of emergent bradycardia associated with the use of carvedilol and metoprolol in routine clinical practice.
Topics: Adrenergic alpha-1 Receptor Antagonists; Bradycardia; California; Carbazoles; Carvedilol; Comorbidit | 2013 |
Prognostic significance of beta-blocker up-titration in conjunction with cardiac resynchronization therapy in heart failure management.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Bradycardia; Carbazoles; Cardiac Resynchronizatio | 2016 |
Usefulness of carvedilol in the treatment of chronic aortic valve regurgitation.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Aortic Valve Insufficiency; Atrial Natri | 2011 |
[Use of carvedilol in daily practice].
Topics: Adrenergic beta-Antagonists; Bradycardia; Carbazoles; Cardiology; Carvedilol; Coronary Disease; Drug | 1999 |
Remote titration of carvedilol for heart failure patients by advanced practice nurses.
Topics: Adrenergic beta-Antagonists; Aged; Bradycardia; Carbazoles; Carvedilol; Clinical Protocols; Cohort S | 2004 |
Prophylactic pacemaker use to allow beta-blocker therapy in patients with chronic heart failure with bradycardia.
Topics: Adrenergic beta-Antagonists; Bradycardia; Carbazoles; Carvedilol; Comorbidity; Cost-Benefit Analysis | 2006 |
Beta-blockers for heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Bradycardia; Carbazoles; Carvedilol; Heart Failure; Humans; | 2000 |